Exchange: NYSEArca·Updated 04:10 PM EST

HDG News

News
all
press releases
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism
The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.
Stocktwits
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism
The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.
Stocktwits
More News
CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.
Stocktwits
Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.
Stocktwits
The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.
Stocktwits
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.
Stocktwits

Advertisement|Remove ads.